The study used SAR439459 to demonstrate its ability, in preclinical models with syngeneic mice, to suppress tumor growth using a single agent and to enhance the efficacy of PD-1 blockade by reversing TGF-β-mediated immune suppression and leading to complete and sustained tumor regression. Here, TGFB1 is linked to neoplasm.